Description
Reveromycin A is an osteoclast-targeting antibiotic compound that exhibits anti-resorptive and antifungal activities. In animal models of juvenile Paget’s disease, reveromycin A inhibits bone resorption and normalizes bone turnover and formation. Reveromycin A inhibits isoleucyl-tRNA synthase, preventing protein synthesis in osteoclasts; this induces apoptosis and prevents resorption in vivo. Additionally, reveromycin A inhibits bone metastasis by lung cancer cells.
References
Yabumoto T, Miyazawa K, Tabuchi M, et al. Stabilization of tooth movement by administration of reveromycin A to osteoprotegerin-deficient knockout mice. Am J Orthod Dentofacial Orthop. 2013 Sep;144(3):368-80. PMID: 23992809.
Hiraoka K, Zenmyo M, Watari K, et al. Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Sci. 2008 Aug;99(8):1595-602. PMID: 18754872.
Woo JT, Kawatani M, Kato M, et al. Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4729-34. PMID: 16537392.